Accessibility Menu
 
Fennec Pharmaceuticals logo

Fennec Pharmaceuticals

(NASDAQ) FENC

Current Price$6.93
Market Cap$238.91M
Since IPO (2004)-94%
5 Year+12%
1 Year+12%
1 Month+7%

Fennec Pharmaceuticals Financials at a Glance

Market Cap

$238.91M

Revenue (TTM)

$44.85M

Net Income (TTM)

$10.18M

EPS (TTM)

$-0.34

P/E Ratio

-20.14

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Price

$6.93

Volume

9,541

Open

$6.89

Previous Close

$6.93

Daily Range

$6.89 - $7.27

52-Week Range

$5.65 - $9.92

FENC News

FENC: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fennec Pharmaceuticals

Industry

Biotechnology

Employees

35

CEO

Jeffrey S Hackman

Headquarters

Research Triangle Park, NC 27709, US

FENC Financials

Key Financial Metrics (TTM)

Gross Margin

92%

Operating Margin

-15%

Net Income Margin

-23%

Return on Equity

-68%

Return on Capital

-11%

Return on Assets

-15%

Earnings Yield

-4.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$238.91M

Shares Outstanding

34.48M

Volume

9.54K

Avg. Volume

170.99K

Financials (TTM)

Gross Profit

$41.59M

Operating Income

$6.86M

EBITDA

$6.86M

Operating Cash Flow

$12.47M

Capital Expenditure

$0.00

Free Cash Flow

$12.47M

Cash & ST Invst.

$36.72M

Total Debt

$0.00

Fennec Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$13.99M

+76.5%

Gross Profit

$12.20M

+68.1%

Gross Margin

87.20%

N/A

Market Cap

$238.91M

N/A

Market Cap/Employee

$7.47M

N/A

Employees

32

N/A

Net Income

$5.22M

-163.1%

EBITDA

$3.06M

-236.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$36.72M

+403.4%

Accounts Receivable

$23.18M

+79.9%

Inventory

$1.56M

+47.4%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-14.53%

N/A

Return on Invested Capital

-11.40%

N/A

Free Cash Flow

$5.96M

-304.5%

Operating Cash Flow

$5.96M

-304.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OBIOOrchestra BioMed Holdings, Inc.
$4.04+2.80%
AVTXAvalo Therapeutics, Inc.
$21.57-5.68%
EPRXEupraxia Pharmaceuticals Inc.
$7.45-0.27%
RNACCartesian Therapeutics, Inc.
$8.65+6.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
RXTRackspace Technology
$5.49+0.56%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.62+0.08%
IRENIren
$61.20+0.08%
NOKNokia
$12.82+0.04%

Questions About FENC

What is the current price of Fennec Pharmaceuticals?

Fennec Pharmaceuticals is trading at $6.93 per share.

What is the 52-week range for Fennec Pharmaceuticals?

Over the past 52 weeks, Fennec Pharmaceuticals has traded between $5.65 and $9.92.

How much debt does Fennec Pharmaceuticals have?

As of the most recent reporting period, Fennec Pharmaceuticals reported total debt of N/A.

How much cash does Fennec Pharmaceuticals have on hand?

Fennec Pharmaceuticals reported $36.79M in cash and cash equivalents in its most recent financial results.

What is Fennec Pharmaceuticals’s dividend yield?

Fennec Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.